The Bull Rankings scorecard — our quality-growth score is 73.8 / 100, built from three pillars scored 0–100: Quality 92, Growth 84, Value 52 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 13% a year next year, fading to 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Exponent’s quality‑growth score of 73.8 is anchored by a 92 in Quality, a 84 in Growth, and a 52 in Value. The 92 tells us the business is built on a durable engineering consulting moat, while the 84 shows it is still adding revenue at a healthy pace. The Value pillar, sitting at 52, signals the stock is priced on the cheaper side of its sector peers, not over‑valued. The single most compelling argument for owning EXPO today is the combination of high free‑cash‑flow generation ($109 m TTM) and strong profitability (profit margin 17.7 %) that supports a ROE of 38.7 %. These figures prove the firm can keep compounding returns without diluting shareholders, a fact echoed by the model signal “Buying back stock.”
What the business actually is
Exponent, Inc. delivers science and engineering consulting across two main segments: Engineering and Other Scientific, Environmental and Health. The Engineering arm covers biomechanics, biomedical engineering, civil and structural engineering, construction consulting, data sciences, electrical engineering, mechanical engineering, materials and corrosion engineering, and vehicle engineering. The Other Scientific segment tackles chemical regulation, polymer and chemistry, thermal sciences, and metallurgical corrosion. Clients range from federal agencies and utilities to private industry, all of whom rely on Exponent’s expertise to solve complex technical problems. Revenue growth of 12.8 % YoY is driven mainly by the Engineering segment, where repeat engagements and long‑term contracts keep the pipeline robust.
Why it can (or can't) keep compounding
The durability case rests on margin resilience and capital efficiency. With a profit margin of 17.7 % and ROE of 38.7 %, Exponent turns a modest revenue base into outsized returns. The firm’s debt‑to‑equity of 0.28 keeps leverage low, allowing it to fund growth internally. The model’s “Durable high returns” signal confirms that the firm’s return on invested capital consistently exceeds the cost of capital, a moat that competitors—often larger but less specialized—cannot replicate quickly. The free‑cash‑flow growth implied by the reverse‑DCF (~13 % in year 1, tapering to 3 % by year 10) aligns closely with the current 12.8 % revenue growth, suggesting the market already prices in a realistic, sustainable expansion path.
The valuation question
At a current price of $68.3 and a P/E of 30.6, Exponent trades at a premium to its 12‑month consensus target of $84 and a range of $72–$90. The PEG ratio of 2.03 indicates the market expects growth to slow somewhat, yet the reverse‑DCF implied growth of 13 % in the first year is only marginally higher than the actual 12.8 % revenue growth. This proximity means the price already incorporates a modest optimism about future expansion. If the implied growth were significantly above the actual growth, the stock would be over‑priced; if it were below, the market would be pessimistic. Here, the numbers suggest the market is neither overly bullish nor bearish—just slightly hopeful that Exponent can sustain its current trajectory.
The bear case
The weakest pillar, Value at 52, signals that the stock is not a bargain relative to peers. A P/E of 30.6 is high for a company with a PEG of 2.03 and a profit margin of 17.7 %. If Exponent’s revenue growth were to stall or decline, the high multiple would quickly become unsustainable. The single most concrete warning is the reverse‑DCF implied growth of 13 %—if actual revenue growth drops below 12.8 %, the model’s valuation would overstate the firm’s worth. A sudden dip in free‑cash‑flow or a rise in debt‑to‑equity above 0.28 would also erode the quality moat.
What would change our mind
- Revenue growth falling below 12.8 % for two consecutive quarters would invalidate the implied 13 % growth assumption, turning the valuation upside down.
- Profit margin slipping below 17.7 % would compress ROE and free‑cash‑flow, weakening the durable returns signal.
- Debt‑to‑equity rising above 0.28 would increase financial risk and reduce the firm’s ability to fund buybacks, eroding the quality pillar.
If any of these thresholds are breached, the balance tips toward a bearish stance, and the current price would no longer justify the implied growth trajectory.